Sibutramine use in pregnancy: Report of two cases

被引：10

作者：

Kadioglu, M ^{[1
]}

Ulku, C

Yaris, F

Kesim, M

Kalyoncu, NI

Yaris, E

机构：

[1] Karadeniz Tech Univ, Sch Med, Dept Pharmacol, TR-61187 Trabzon, Turkey

[2] Karadeniz Tech Univ, Sch Med, Dept Family Med, TR-61187 Trabzon, Turkey

来源：

BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY | 2004年 / 70卷 / 08期

关键词：

pregnancy; sibutramine; obesity;

D O I：

10.1002/bdra.20052

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

BACKGROUND: Sibutramine is a drug used for the medical treatment of obesity. No data are available on sibutramine use in pregnancy. We report the fetal outcomes of two pregnant women exposed to sibutramine. CASES: The first woman was exposed to 10 mg/day of sibutramine during gestational weeks 4-6. The second woman was exposed to 10 mg/day of sibutramine during gestational weeks 5-8. At weeks 37 and 39, they delivered healthy infants. CONCLUSIONS: To our knowledge, this is the first report of sibutramine exposure in pregnancy. These cases may contribute to the knowledge about sibutramine use during pregnancy. (C) 2004 Wiley-Liss, Inc.

引用

页码：545 / 546

页数：2

共 5 条

[1]

Alemany M, 2003, IDRUGS, V6, P566

[2] What should we do about overweight and obesity? [J].

Caterson, ID .

MEDICAL JOURNAL OF AUSTRALIA, 1999, 171 (11-12) :599-600

[3] Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity [J].

Gokcel, A ;

Gumurdulu, Y ;

Karakose, H ;

Ertorer, EM ;

Tanaci, N ;

Tutuncu, NB ;

Guvener, N .

DIABETES OBESITY & METABOLISM, 2002, 4 (01) :49-55

[4]

SANDERSBUSH E, 2001, PHARMACOL BASIS THER, P278

[5]

Schurgin Sunita, 2003, Nutr Clin Care, V6, P27

← 1 →